We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cells Not Progenitors Can Trigger Skin Cancer Growth

By LabMedica International staff writers
Posted on 21 Jul 2016
Cancer researchers have discovered that stem cells can initiate development of malignant skin tumors, while progenitor cells are limited to triggering only benign growths.

A progenitor cell is similar to a stem cell, in that it has a tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its "target" cell. More...
The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can divide only a limited number of times.

Investigators at the Université Libre de Bruxelles (Belgium) and the University of Cambridge (United Kingdom) sought to identify the type of cells that initiated formation of basal cell carcinoma, the most common form of skin cancer. To this end they assessed the impact of oncogenic hedgehog signaling in distinct cell populations and their capacity to induce cancer growth.

They reported in the July 8, 2016, online edition of the journal Nature that in a transgenic mouse model system only stem cells, and not progenitors, were competent to initiate tumor formation upon oncogenic hedgehog signaling. Clones derived from stem cells were able to overcome apoptosis and continue to divide and proliferate unchecked, developing into basal cell carcinoma. In contrast, the growth of clones derived from progenitor cells was checked by increasing levels of apoptosis, leading to the formation of benign lesions.

"It is incredibly rare to identify a cancer cell of origin and until now no one has been able to track what happens on an individual level to these cells as they mutate and proliferate," said senior author Dr. Cédric Blanpain, a professor at the Université Libre de Bruxelles. "We now know that stem cells are the culprits: when an oncogene in a stem cell becomes active, it triggers a chain reaction of cell division and proliferation that overcomes the cell's safety mechanisms."

"While this has solved a long-standing scientific argument about which cell types can lead to invasive skin tumors, it is far more than just a piece of esoteric knowledge," said contributing author Dr. Benjamin Simons, professor of physics at the University of Cambridge. "It suggests to us that targeting the pathways used in regulating cell fate decisions - how stem cells choose between cell proliferation and differentiation - could be a more effective way of halting tumors in their tracks and lead to potential new therapies."

Related Links:
Université Libre de Bruxelles
University of Cambridge

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New research demonstrates that an electrical “fingerprint” on extracellular vesicles can be exploited to enrich cancer-associated signals (Image Credit: Shutterstock)

Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer

Pancreatic cancer is often diagnosed only after it has spread, contributing to a five-year survival rate of 13%. Standard blood-based analyses can struggle to distinguish tumor signals from the background... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.